New drug aims to tame tumor-triggered low blood sugar in rare cancer patients
NCT ID NCT06881992
First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times
Summary
This study tests a new medicine called ersodetug for people whose tumors cause dangerously low blood sugar that standard treatments can't control. About 16 adults with insulin-producing tumors will receive the drug alongside their usual care. The main goal is to see if ersodetug reduces the need for intravenous sugar to keep blood sugar levels safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 16 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist * Male or female participants of ≥18 years of age who provide written informed consent. * Clinical diagnosis of neuroendocrine tumor (NET) (ICT or NICT) with biochemical evidence of tumor hyperinsulinism (hypoglycemia with inappropriately elevated insulin or insulin-like growth factor (IGF)/variant suppression) confirmed via laboratory assessment who have failed to achieve adequate control of hypoglycemia with usual SOC anti-hypoglycemic therapies, per investigator judgement. * Currently requiring IV glucose infusion and/or parenteral nutrition for ≥7 days for the management of refractory hypoglycemia (prior to administration of the 1st dose of ersodetug). Exclusion Criteria: * Evidence of active infection including human immunodeficiency virus, hepatitis B, or hepatitis C (excluding immunization patterns). * Treatment with an investigational drug or device within 30 days or 5 half-lives of the investigational drug (whichever is longer), however, if the treating physician and Medical Monitor consider no significant risk of drug-drug interaction and potential benefit outweighs the risk then the participant may be allowed to participate. Participation in registries and purely diagnostic studies is allowed * Any out-of-range laboratory value at screening (other than glucose) that is assessed as clinically significant by the investigator. Laboratory or radiographic abnormalities that are considered related to the underlying disease (tumor) or associated therapies and do not pose additional safety risk for study participation per investigator and Medical Monitor may be allowed. * Known allergy or sensitivity to ersodetug or any component of the drug. * Any organ condition, concomitant disease (e.g., psychiatric illness, severe alcoholism, or drug abuse, cardiac, hepatic, or kidney disease), or other abnormality that itself, or the treatment of which in the opinion of the investigator and/or Sponsor's Medical Monitor would pose an unacceptable risk to the participant in the study. * Estimated life expectancy (additional lifespan) due to underlying disease (tumor) is \<8 weeks.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tumor hyperinsulinism (tumor hi) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
13 sites in 5 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Investigative Site
RECRUITINGChicago, Illinois, 60637, United States
-
Investigative Site
RECRUITINGBethesda, Maryland, 20892, United States
-
Investigative Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
Investigative Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Investigative Site
RECRUITINGNew York, New York, 10021, United States
-
Investigative Site
RECRUITINGCanton, Ohio, 44718, United States
-
Investigative Site
RECRUITINGPortland, Oregon, 97239, United States
-
Investigative Site
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Investigative Site
RECRUITINGClichy, Île-de-France Region, 92110, France
-
Investigative Site
RECRUITINGRotterdam, South Holland, 3015, Netherlands
-
Investigative Site
RECRUITINGBasel, Canton Basel-Stadt, CH-4001, Switzerland
-
Investigative Site
RECRUITINGSaint Johns Wood, London, NW3 2QG, United Kingdom
-
Investigative Site
RECRUITINGWithington, Manchester, M20 4BX, United Kingdom